Page 106 - NobleCon21

Health Care
Date November 24, 2025 Health Care
52wk High $19.51
52wk Low $0.51 Jupiter Neurosciences, Inc. JUNS $1.19
1001 North US Highway 1
Jupiter, FL 33477

(USD - in millions) jupiterneurosciences.com
Market Cap 40.6
Enterprise 40.1
Basic Shares Out. 34.43 COMPANY OVERVIEW
Float 16.48
Institutional Holdings 3.95% Detailed Analysis:Channelchek.com
Short Interest 0.02
Avg. 90-Day Volume 0.13 JUNS is a biotech company with a dual strategy. One is clinically
focused with a proprietary product, JOTROL, in a Phase Il for
Parkinson's Disease. The other is a Direct-To-Consumer approach with
product line, Nugevia.com, targeting the explosively growing Longevity
EPS Data and Healthspan market. We are well funded through a non-toxic SEPA
deal to be able to fully complete the Parkinson's trial and aggressively
2022 2023 2024 launch the Nugevia product line.
CQ1 N/A N/A N/A
CQ2 N/A N/A N/A

CQ3 N/A N/A (0.02)
CQ4 N/A N/A (0.05)
CY N/A N/A (0.08) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.00
ROE (ttm) NM
Debt-to-Total Cap. (mrq) 75.86
Fiscal Year End 31-Dec
1001 North US Jupiter FL 33477

Key Executives
CEO: Rosen, Christer
CFO: Elmasri, Saleem
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures